Factor Model (net -3.4)
Factor Model
net -3.4 6.4 / 10Gyre acquires Cullgen for $300M to expand protein degrader platform
Watch: Monitor Q2 2026 closing progress and regulatory approval timelines. Watch for integration updates on manufacturing efficiency gains and updates on Cullgen's lead candidates moving through the clinic — these will telegraph whether Gyre can execute this expansion without derailing its own development timelines.
Gyre Therapeutics announced an all-stock acquisition of clinical-stage biotech Cullgen for approximately $300 million. The deal, expected to close in early Q2 2026, combines U.S. and China-based capabilities in discovery, manufacturing, and commercialization of targeted protein degrader and degrader antibody conjugate therapies. Cullgen's CEO Ying Luo will join Gyre as President and COO, while existing Gyre chairman Ping Zhang remains in position.
This acquisition expands Gyre's pipeline depth in a high-potential modality — protein degraders are an increasingly validated drug class with multiple late-stage candidates in development across the industry. The integration of Cullgen's China-based manufacturing capability strengthens supply-chain resilience while the all-stock structure preserves Gyre's cash for clinical development.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when GYRE changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.